Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 87

1.

Type 2 diabetes: Evolving concepts and treatment.

Miller E, Aguilar RB, Herman ME, Schwartz SS.

Cleve Clin J Med. 2019 Jul;86(7):494-504. doi: 10.3949/ccjm.86a.17107. Review.

2.

Incidence and Mortality of Adults With Pulmonary Hypertension and Congenital Heart Disease.

Schwartz SS, Madsen N, Laursen HB, Hirsch R, Olsen MS.

Am J Cardiol. 2018 Jun 15;121(12):1610-1616. doi: 10.1016/j.amjcard.2018.02.051. Epub 2018 Mar 14.

PMID:
29655882
3.

Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes.

Herman ME, O'Keefe JH, Bell DSH, Schwartz SS.

Prog Cardiovasc Dis. 2017 Nov - Dec;60(3):422-434. doi: 10.1016/j.pcad.2017.09.001. Epub 2017 Sep 25. Review.

PMID:
28958751
4.

A Unified Pathophysiological Construct of Diabetes and its Complications.

Schwartz SS, Epstein S, Corkey BE, Grant SFA, Gavin Iii JR, Aguilar RB, Herman ME.

Trends Endocrinol Metab. 2017 Sep;28(9):645-655. doi: 10.1016/j.tem.2017.05.005. Epub 2017 Jun 16. Review.

PMID:
28629897
5.

An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.

Messana JA, Schwartz SS, Townsend RR.

Vasc Health Risk Manag. 2017 Feb 17;13:43-54. doi: 10.2147/VHRM.S105721. eCollection 2017. Review.

6.

Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus.

Schwartz SS, Zangeneh F.

Postgrad Med. 2016 Nov;128(8):828-838. Epub 2016 Aug 25. Review.

PMID:
27458683
7.

Response to Comment on Schwartz et al. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema. Diabetes Care 2016;39:179-186.

Schwartz SS, Epstein S, Corkey BE, Grant SF, Gavin JR 3rd, Aguilar RB.

Diabetes Care. 2016 Aug;39(8):e129-30. doi: 10.2337/dci16-0011. No abstract available.

PMID:
27457644
8.

Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy's safety profile.

Schwartz SS, Jellinger PS, Herman ME.

Postgrad Med. 2016 Aug;128(6):609-19. doi: 10.1080/00325481.2016.1191955. Epub 2016 Jun 3. Review.

PMID:
27210018
9.
10.

Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.

Schwartz SS, Ahmed I.

Curr Med Res Opin. 2016 May;32(5):907-19. doi: 10.1185/03007995.2016.1151774. Epub 2016 Feb 26. Review.

PMID:
26854518
11.

The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema.

Schwartz SS, Epstein S, Corkey BE, Grant SF, Gavin JR 3rd, Aguilar RB.

Diabetes Care. 2016 Feb;39(2):179-86. doi: 10.2337/dc15-1585.

12.

THE RATIONALE FOR USE OF INCRETINS IN THE MANAGEMENT OF NEW ONSET DIABETES AFTER TRANSPLANTATION (NODAT).

Sadhu AR, Schwartz SS, Herman ME.

Endocr Pract. 2015 Jul;21(7):814-22. doi: 10.4158/EP14569.RA. Epub 2015 Mar 18. Review.

PMID:
25786557
13.

Systolic Blood Pressure Control Among Individuals With Type 2 Diabetes: A Comparative Effectiveness Analysis of Three Interventions.

Espeland MA, Probstfield J, Hire D, Redmon JB, Evans GW, Coday M, Lewis CE, Johnson KC, Wilmoth S, Bahnson J, Dulin MF, Green JB, Knowler WC, Kitabchi A, Murillo AL, Osei K, Rehman SU, Cushman WC; Look AHEAD Research Group; ACCORD Study Group.

Am J Hypertens. 2015 Aug;28(8):995-1009. doi: 10.1093/ajh/hpu292. Epub 2015 Feb 9.

14.

Practical implementation of incretin-based therapy in hospitalized patients with type 2 diabetes.

Schwartz SS, DeFronzo RA, Umpierrez GE.

Postgrad Med. 2015 Mar;127(2):251-7. doi: 10.1080/00325481.2015.996504. Epub 2014 Dec 30. Review.

PMID:
25547241
15.

Optimizing glycemic control and minimizing the risk of hypoglycemia in patients with type 2 diabetes.

Schwartz SS.

Drugs Context. 2013 May 22;2013:212255. doi: 10.7573/dic.212255. eCollection 2013 May 22.

16.

Impact of weight loss on ankle-brachial index and interartery blood pressures.

Espeland MA, Lewis CE, Bahnson J, Knowler WC, Regensteiner JG, Gaussoin SA, Beavers D, Johnson KC; Look AHEAD Research Group.

Obesity (Silver Spring). 2014 Apr;22(4):1032-41. doi: 10.1002/oby.20658. Epub 2014 Feb 24.

17.

Human cardiovascular disease IBC chip-wide association with weight loss and weight regain in the look AHEAD trial.

McCaffery JM, Papandonatos GD, Huggins GS, Peter I, Erar B, Kahn SE, Knowler WC, Lipkin EW, Kitabchi AE, Wagenknecht LE, Wing RR; Genetic Subgroup of Look AHEAD; Look AHEAD Research Group.

Hum Hered. 2013;75(2-4):160-74. doi: 10.1159/000353181. Epub 2013 Sep 27.

18.

Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.

Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, Evans M, Foreyt JP, Ghazarian S, Gregg EW, Harrison B, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montez MG, Murillo A, Nathan DM, Patricio J, Peters A, Pi-Sunyer X, Pownall H, Reboussin D, Regensteiner JG, Rickman AD, Ryan DH, Safford M, Wadden TA, Wagenknecht LE, West DS, Williamson DF, Yanovski SZ.

N Engl J Med. 2013 Jul 11;369(2):145-54. doi: 10.1056/NEJMoa1212914. Epub 2013 Jun 24. Erratum in: N Engl J Med. 2014 May 8;370(19):1866.

19.

A practice-based approach to the 2012 position statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Schwartz SS.

Curr Med Res Opin. 2013 Jul;29(7):793-9. doi: 10.1185/03007995.2013.798637. Epub 2013 May 10.

PMID:
23614630
20.

The long-term effectiveness of a lifestyle intervention in severely obese individuals.

Unick JL, Beavers D, Bond DS, Clark JM, Jakicic JM, Kitabchi AE, Knowler WC, Wadden TA, Wagenknecht LE, Wing RR; Look AHEAD Research Group.

Am J Med. 2013 Mar;126(3):236-42, 242.e1-2. doi: 10.1016/j.amjmed.2012.10.010.

Supplemental Content

Loading ...
Support Center